<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00277095</url>
  </required_header>
  <id_info>
    <org_study_id>UM02</org_study_id>
    <nct_id>NCT00277095</nct_id>
  </id_info>
  <brief_title>ProACT Therapy for the Treatment of Stress Urinary Incontinence in Males</brief_title>
  <acronym>ProACT</acronym>
  <official_title>Clinical Investigation of the ProACT Adjustable Continence Therapy for Treatment of Post-Prostatectomy Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uromedica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uromedica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and effectiveness of a minimally invasive
      surgical procedure in up to 109 male patients. The ProACT device is designed to treat men who
      have stress urinary incontinence arising from intrinsic sphincter deficiency following an
      operation performed on the prostate for cancer or for benign prostatic hyperplasia. Two
      adjustable balloons (one on each side of the urethra) are implanted to treat urinary stress
      incontinence.

      The results will be analyzed to demonstrate the effects of the device as well as its
      associated risks. Therapeutic success will be based on whether patients demonstrate at least
      a 50% reduction in pad weight at 18 months follow-up compared to the pad weight results at
      baseline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, non-randomized multi-center investigation. Multiple measurements
      using 24 hour pad weight and pad count, validated questionnaires, voiding diaries will be
      used to evaluate the achievement of the study objectives. Subjects will be followed for a
      minimum of 18 months following implantation. Subjects will be requested to continue annual
      follow-ups through the FDA approval.

      The purpose of the study is to evaluate the safety and effectiveness of a minimally invasive
      surgical procedure in up to 109 male patients. The ProACT device is designed to treat men who
      have stress urinary incontinence arising from intrinsic sphincter deficiency following an
      operation performed on the prostate for cancer or for benign prostatic hyperplasia. Two
      adjustable balloons (one on each side of the urethra) are implanted to treat urinary stress
      incontinence.

      The results will be analyzed to demonstrate the effects of the device as well as its
      associated risks. Therapeutic success will be based on whether patients demonstrate at least
      a 50% reduction in pad weight at 18 months follow-up compared to the pad weight results at
      baseline.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2005</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy: Demonstrate the Efficacy of the ProACT Device in Reducing Incontinence as Measured by the 24-hour Pad Weight at 18 Months Compared to Baseline. A Subject is a Success if he Demonstrates a 50% Reduction.</measure>
    <time_frame>18 month follow-up</time_frame>
    <description>The percentage of participants with 50% reduction in pad weight.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>ProACT (Adjustable Continence Therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation with ProACT (Adjustable Continence Therapy), Single Arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ProACT (Adjustable Continence Therapy)</intervention_name>
    <description>Implantable device to reduce urinary stress incontinence</description>
    <arm_group_label>ProACT (Adjustable Continence Therapy)</arm_group_label>
    <other_name>ProACT,Adjustable Incontinence therapy for Males</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergone either a radical prostatectomy, transurethral resection of the prostate or
             other prostate surgery at least 12 months prior without radiation therapy

          -  Demonstrate primary stress urinary incontinence

          -  Male subjects at least 45 years of age

          -  Willing and able to undergo surgical implantation of the ProACT devices

          -  Willing and able to comply with the follow-up requirements

          -  Willing and able to forego any other surgical urinary incontinence treatments while
             participating in the study

          -  Willing and able to sign the informed consent

          -  Positive 24 hour pad weight tests (greater than or equal to 8 gram pad weight increase
             demonstrated in two 24-hour pad weight tests)

          -  Experiences at least 3 incontinence episodes per day during two baseline voiding
             diaries.

          -  Negative Urine culture

          -  No recurrent stricture at the anastamosis

          -  No known urogenital malignancy other than previously treated prostate cancer

          -  Physician determines subject to be suitable surgical candidate

        Exclusion Criteria:

          -  Primarily Urge incontinence

          -  Detrusor instability or over-activity

          -  Residual volume greater that 100 ml or greater than 25% of the total bladder capacity
             after voiding.

          -  Subject has/had or is suspected of having bladder cancer

          -  History of recurrent bladder stones

          -  Neurogenic bladder that is atonic or has detrusor sphincter dyssynergia

          -  Known hemophilia or a bleeding disorder

          -  Abnormal PSA (Prostate Specific Antigen), according to sites laboratory standards,
             unless further investigation confirms no underlying prostate malignancy.

          -  Known sever contrast solution allergy

          -  Has a genitourinary mechanical prosthesis other than previous sling procedure (e.g.,
             Artificial Urinary sphincter, implantable penile prosthesis)

          -  Has a urethral stricture that prevents passage of an 18 F cystoscope or has had more
             than one urethrotomy

          -  Undergone bulking procedure within 6 months of the baseline assessment

          -  Subject is currently enrolled or plans to enroll in another device or drug clinical
             trial.

          -  Subject is currently using an indwelling catheter or condom catheter for treatment of
             incontinence and is not willing to discontinue use at least 4 weeks prior to baseline
             assessment.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Cook, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Uromedica, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Pelvic Clinic</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indian River Urology</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological Surgeons</name>
      <address>
        <city>Kankakee</city>
        <state>Illinois</state>
        <zip>60901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Urology</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Urology Care</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Can-Med Clinical Research Inc.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T5G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS-Fleurimont</name>
      <address>
        <city>Fleurimont</city>
        <state>Quebec</state>
        <zip>J1H5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Bay of Plenty (formerly Promed Urology)</name>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm?id=3425</url>
    <description>ProACT Adjustable Continence for Men Premarket Approval (PMA) 11/24/2015</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2006</study_first_submitted>
  <study_first_submitted_qc>January 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2006</study_first_posted>
  <results_first_submitted>January 30, 2013</results_first_submitted>
  <results_first_submitted_qc>January 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2016</results_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary Incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Implantable Device</title>
          <description>ProACT Implantable device for treatment of post-prostatectomy stress urinary incontinence in males.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="124">Anatomy of 1 patient did not allow ProACT to be implanted, hence only 123 patients were implanted.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103">Details of patients who did not complete study are given below.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Explanted</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ProACT</title>
          <description>Implantable device</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="124"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.7" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Efficacy: Demonstrate the Efficacy of the ProACT Device in Reducing Incontinence as Measured by the 24-hour Pad Weight at 18 Months Compared to Baseline. A Subject is a Success if he Demonstrates a 50% Reduction.</title>
        <description>The percentage of participants with 50% reduction in pad weight.</description>
        <time_frame>18 month follow-up</time_frame>
        <population>As followed analysis of all patients who were treated and reached the 18 month follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Urine Loss ( in Grams)</title>
            <description>24 hour pad weight(in grams) demonstrating 50% reduction in urine loss (in grams)over 18th month</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Efficacy: Demonstrate the Efficacy of the ProACT Device in Reducing Incontinence as Measured by the 24-hour Pad Weight at 18 Months Compared to Baseline. A Subject is a Success if he Demonstrates a 50% Reduction.</title>
          <description>The percentage of participants with 50% reduction in pad weight.</description>
          <population>As followed analysis of all patients who were treated and reached the 18 month follow-up visit</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.6" lower_limit="50" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ProACT</title>
          <description>Implantable device</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICH GCP April 1996</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Low Heart Rate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcerative Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>CVA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>ICH GCP April 1996</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Oncological/hematologic Condition</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Condition</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Condition</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other Non Genitourinary</sub_title>
                <counts group_id="E1" events="54" subjects_affected="40" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pain, nongenitourinary</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Genitourinary</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Balloon Migration</sub_title>
                <counts group_id="E1" events="30" subjects_affected="21" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Perforation During Implant</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Device Failure, Leakage</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Balloon Erosion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Device Failure, other</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Other Genitourinary</sub_title>
                <counts group_id="E1" events="79" subjects_affected="46" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pain Genitourinary</sub_title>
                <counts group_id="E1" events="47" subjects_affected="35" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Worsening Incontinence</sub_title>
                <counts group_id="E1" events="37" subjects_affected="35" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Infection, Urinary Tract</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Retention</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermotologic</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sabitha R Shriram</name_or_title>
      <organization>Uromedica</organization>
      <phone>763-694-9880 ext 216</phone>
      <email>sshriram@uromedica-inc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

